Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
Type:
Grant
Filed:
September 24, 2014
Date of Patent:
April 21, 2015
Assignee:
Vivus, Inc.
Inventors:
Thomas Najarian, Peter Y. Tam, Leland F. Wilson
Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
Type:
Grant
Filed:
September 24, 2014
Date of Patent:
April 21, 2015
Assignee:
Vivus, Inc.
Inventors:
Thomas Najarian, Peter Y. Tam, Leland F. Wilson
Abstract: A fabric, fiber, hair or skin conditioning additive for use in a liquid cleaning product is encapsulated within a shell comprising a silicon-containing polymer network.
Type:
Grant
Filed:
October 15, 2009
Date of Patent:
April 14, 2015
Assignee:
Dow Corning Corporation
Inventors:
Thomas Bekemeier, Lorry Deklippel, Tatiana Dimitrova, Russell Elms, Fabrizio Galeone, Bertrand Lenoble, Leon Marteaux, Josef Roidl, Martin Severance, Stephane Ugazio, Brett Zimmerman
Abstract: A process for preparing silicate shell microcapsules comprises adding a water reactive silicon compound to an oil in water emulsion, thereby condensing and polymerizing the water reactive silicon compound to form silicate shell microcapsules having a core comprising the oil phase of the said emulsion. The water reactive silicon compound comprises a tetraalkoxysilane and an alkoxysilane having an amino or quaternary ammonium substituted alkyl group.
Type:
Grant
Filed:
October 15, 2009
Date of Patent:
April 14, 2015
Assignee:
Dow Corning Corporation
Inventors:
Thomas Bekemeier, Lorry Deklippel, Tatiana Dimitrova, Russell Elms, Fabrizio Galeone, Bertrand Lenoble, Leon Marteaux, Josef Roidl, Martin Severance, Stephane Ugazio, Brett Zimmerman
Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.
Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
March 24, 2015
Assignee:
KLOX Technologies Inc.
Inventors:
Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
Abstract: A method of covalently bonding a cyclic nitroxide radical compound to a hydrophobic block of a specific hydrophylic-phobic block copolymer, and polymerized cyclic nitroxide radical compound copolymerized in this manner, as well as use of such a compound, for instance, in the medical field are provided. The compound demonstrates long term stability in vivo under reductive environment.
Abstract: A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay.
Abstract: There is provided a wound healing composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
March 10, 2015
Assignee:
KLOX Technologies Inc.
Inventors:
Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
Abstract: An efficient and simple process to obtain a concentrate that includes over 80% in weight of ethyl esters of ?-3 fatty acids based on a composition of matter that contains esters of ?-3 fatty acids or free ?-3 fatty acids that comprises the stages of: a) contacting the composition of matter with ethanol of at least 96% in weight and a hydroxide of an alkali metal at a temperature between 60 and 200° C. to form a liquid mixture that includes alkaline salts of fatty acids; b) cool the liquid mixture to a temperature between 50 and ?20° C. to form a solid phase and a liquid phase and separate the liquid phase from the solid phase; c) contact the separated liquid phase of stage b) with an acid to form an acidified mixture with a water content under 10%, where the mixture consists of a solid phase that includes the alkali metal salt of the acid and a liquid phase that comprises ?-3 fatty acids; d) heat the mixture of stage c) between 50 to 150° C.
Type:
Grant
Filed:
December 25, 2011
Date of Patent:
February 17, 2015
Assignee:
Golden Omega S.A.
Inventors:
Juvenal Antonio Sepulveda Reyes, Miriam Rosa Berrios Cornejo, Miguel Angel Fuenzalida Dias, Alejandro Markovits Rojas, Thomas Francis Harting Glade
Abstract: Effervescent tablets, powders and granules are provided which may be dissolved in water to produce an effervescent rehydrating beverage. The effervescent tablet, powder and granule compositions of the invention deliver electrolytes and carbohydrates at levels that provide hypotonic, isotonic or slightly hypertonic solution when dissolved in water, with acceptable taste.
Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent.
Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
December 16, 2014
Assignee:
KLOX Technologies Inc.
Inventors:
Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
November 25, 2014
Assignee:
Vivus, Inc.
Inventors:
Thomas Najarian, Peter Y. Tam, Leland F. Wilson